Eli Lilly, a big provider of drugs around the world, has become the latest Western pharmaceutical group embroiled in allegations of malpractice in China.
The US company said it was “deeply concerned” about claims it paid 30 million yuan (US$4.9 million) to doctors to prescribe its diabetic treatments in Shanghai.
GlaxoSmithKline (GSK), Britain’s largest drug company, has seen four of its Chinese executives arrested over bribery allegations and a British consultant who worked for GSK was formally arrested this week.
The allegations against Eli Lilly were made by a former Chinese sales manager for Eli Lilly in China’s 21st Century Business Herald newspaper, prompting the company to admit that it was aware of similar allegations made last year by a former sales manager in the same region.
“At the time of the allegations [last year], we did an exhaustive investigation to search for any evidence of kickbacks,” a company spokesman said.
“The investigation was very thorough and included employee interviews, e-mail monitoring and expense report audits. Although we have not been able to verify these allegations, we take them seriously, and are continuing our investigation,” he said.
The Herald quoted a former Eli Lilly manager as saying “in order to hit sales at rival companies and push the company’s own products, bribes and special payments of all sorts were extremely common at the company.”
Last week the newspaper quoted an unnamed whistleblower as saying that a third drug company, Novartis AG of Switzerland, had paid bribes to doctors to boost drug sales, triggering an internal investigation by that business.
Allegations have also been made against Sanofi of France.
Eli Lilly paid US$29 million to the US authorities last year to settle claims of corrupt practices that included allegations related to China.
These included allegations that it falsified expenses in China between 2006 and 2009 that it allowed its sales representatives to provide gifts and hospitality.
Corruption is believed to be widespread in China, partly due to the very low base salaries paid to the country’s doctors.
NOTABLE SHIFT: By 2030, 50% of all laptops would be assembled in Southeast Asia, while Taiwan would still mostly focus on research and development, a report said Global laptop and desktop computer supply chains are expected to shift significantly away from China in the next 10 years, a Market Intelligence & Consulting Institute (MIC, 產業情報研究所) report said. By 2030, only 40 percent of global laptop production would remain in China, said the report, which was released on Thursday. “The reshuffling of the global supply chain will be one of the most important trends in the next 10 years,” the institute said in the report. “In the long run, key component makers will follow laptop assemblers in moving out of China.” The Taipei-based institute predicted most key component makers
Merck Group Taiwan yesterday said that it plans to invest substantially on expanding its fab in Kaohsiung’s Lujhu District (路竹) to better serve its local customers, including Taiwan Semiconductor Manufacturing Co (TSMC, 台積電). The company said it plans to expand its production space by 50 percent in the next five years and its workforce by about 40 percent, Merck Group Taiwan managing director Dick Hsieh (謝志宏) told a media briefing in Taipei. Hsieh declined to disclose investment details, but said that the latest investment would exceed the total amount Merck has invested in Taiwan over the past few years. Those investments would be
Yageo Corp (國巨), the world’s third-largest supplier of multilayer ceramic capacitors, has formed a strategic alliance with Hon Hai Precision Industry Co (鴻海精密) to develop key electronic components for electric vehicles and digital healthcare, it said yesterday. The alliance is to help Yageo boost its revenue from high-end components for vehicles and industrial, medical and aerospace devices, as well as those used in 5G and Internet-of-Things devices, the company said. The companies signed the strategic alliance agreement at Yageo’s headquarters in New Taipei City’s Sindian District (新店). Their cooperation is to start this quarter, the companies said in a joint statement. “Through the cooperation
SUPPLY CONSTRAINTS: The transferred orders might not provide an immediate revenue boost given local chipmakers’ high utilization rates, a senior analyst said Shares of local contract chipmakers yesterday rose as much as the 10 percent daily limit, as investors bet on orders being transferred from Semiconductor Manufacturing International Corp (SMIC, 中芯國際) after the US imposed export restrictions on the Chinese chipmaker. United Microelectronics Corp (UMC, 聯電) shares soared 10 percent to close at NT$27.5 as 380 million shares changed hands on the Taiwan Stock Exchange. UMC is the world’s No. 3 foundry by revenue, followed by SMIC, according to data from market researcher TrendForce Corp (集邦科技). UMC has product and customer portfolios similar to those of SMIC, TrendForce said, adding that UMC offers 14-nanometer and